Choi Youn Woong
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
COREE Announces Discovery of Microbiome Biomarkers Specific to Diabetes and Obesity Patients 2025-09-26 21:00
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP). 2025-08-18 21:00
Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company 2025-07-30 20:00
Dx&Vx Accelerates Development of Universal COVID-19 Vaccine 2025-05-29 21:03
Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine 2025-01-13 22:00
Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines 2025-01-08 22:00
DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology 2024-11-01 21:00
World-Renowned Scientist Wah Chiu, Stanford University Professor and Honorary Advisor to Pohang City, visited Korea at the invitation of the Coree Group 2024-08-26 21:00
DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment 2024-07-18 21:00
Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success 2024-04-19 21:00
Mr. Chong-Yoon Lim, Chairman of COREE Group emphasizes "Creative destruction and Healthcare 4.0" [New Year Message at X-Twitter SNS] 2024-01-03 22:00
Dx&Vx co-develops a bio-healthcare big data platform with LG CNS 2023-12-20 22:00
DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia 2023-11-24 22:00
DxVx, won the governmental project to develop diagnostic sensor kit for adult diseases 2023-06-09 21:00
Avixgen accelerates the progress on new drug pipeline development 2023-05-24 21:00
DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president 2023-05-16 21:00
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200 2023-03-30 17:39
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx 2022-10-13 21:00
1